|
2015 Journal Article The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in miceKrishnan, S. M., Dowling, J. K., Ling, Y. H., Diep, H., Chan, C. T., Ferens, D., Kett, M. M., Pinar, A., Samuel, C. S., Vinh, A., Arumugam, T. V., Hewitson, T. D., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Latz, E., Mansell, A., Sobey, C. G. and Drummond, G. R. (2015). The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in mice. British Journal of Pharmacology, 173 (4), 752-765. doi: 10.1111/bph.13230 |
|
2015 Journal Article A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesColl, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Muñoz-Planillo, Raúl, Inserra, Marco C., Vetter, Irina, Dungan, Lara S., Monks, Brian G., Stütz, Andrea, Croker, Daniel E., Butler, Mark S., Haneklaus, Moritz, Sutton, Caroline E., Núñez, Gabriel, Latz, Eicke, Kästner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matthew A. and O'Neill, Luke A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21 (3), 248-257. doi: 10.1038/nm.3806 |
|
2015 Conference Publication Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASHMridha, Auvro R., Wree, Alexander, Robertson, Avril A., Teoh, Narci C., Cooper, Matthew A., Feldstein, Ariel E. and Farrell, Geoffrey C. (2015). Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, United States, 13-17 November 2015. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/hep.28175 |
|
2015 Conference Publication Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritisMcGarry, T., Coll, R.C., Robertson, A.A.B., Cooper, M.A., O’Neill, L.A., Veale, D.J. and Fearon, U. (2015). Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis. 35th European Workshop for Rheumatology Research, Budapest, Hungary, 5-7 March 2015. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2015-207259.144 |
|
2015 Conference Publication Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic SyndromesBasiorka, A., Mcgraw, K., Eksioglu, E., Chen, X., Johnson, J., Padron, E., Komrokji, R., Sokol, L., Coll, R., O'Neill, L., Cooper, M., Robertson, A., Wei, S. and List, A. (2015). Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic Syndromes. 13th International Symposium on Myelodysplastic Syndromes (MDS), Washington DC, United States, Apr 29-May 02, 2015. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/S0145-2126(15)30033-3 |
|
2015 Conference Publication An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomesGrinstein, L., Luksch, H., Robertson, A. A. B., Cooper, M. A., Winkler, S. and Rösen-Wolff, A. (2015). An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes. 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases, Dresden, Germany, 30 September - 3 October 2015. BMC. doi: 10.1186/1546-0096-13-S1-O51 |
|
2015 Conference Publication The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA jointMcGarry, T., Robertson, A. A., Orr, C., Coll, R. C., Cooper, M. A., O'Neill, L. A., Veale, D. J. and Fearon, U. (2015). The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA joint. Annual European Congress of Rheumatology, Rome, Italy, 10-13 July 2015. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2015-eular.3985 |
|
2015 Conference Publication Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarctionVan Hout, G. P. J., Bosch, L., Ellenbroek, G. H. J. M., Cooper, M., Van Solinge, W. W., De Jager, S. C. A., Robertson, A., Pasterkamp, G. and Hoefer, I. E. (2015). Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction. Congress of the European Society of Cardiology (ESC), London, United Kingdom, 29 August-2 September 2015. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/eurheartj/ehv400 |
|
2014 Journal Article Natural product and natural product derived drugs in clinical trialsButler, Mark S., Robertson, Avril A. B. and Cooper, Matthew A. (2014). Natural product and natural product derived drugs in clinical trials. Natural Product Reports, 31 (11), 1612-1661. doi: 10.1039/c4np00064a |
|
2014 Journal Article Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destructionGreenhill, Claire J., Jones, Gareth W., Nowell, Mari A., Newton, Zarabeth, Harvey, Ann K., Moideen, Abdul N., Collins, Fraser L., Bloom, Anja C., Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., Rosas, Marcela, Taylor, Philip R., O'Neill, Luke A., Humphreys, Ian R., Williams, Anwen S. and Jones, Simon A. (2014). Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy, 16 (4) 419. doi: 10.1186/s13075-014-0419-y |
|
2014 Conference Publication Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cellsArbore, Giuseppina, Fara, Antonella F., Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke A. J., Lavender, Paul, Cope, Andrew, Lachmann, Helen J. and Kemper, Claudia (2014). Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells. 25th International Complement Workshop, Rio de Janeiro, Brazil, 14-18 September 2014. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/j.molimm.2014.07.010 |
|
2014 Conference Publication What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASHGan, L. T., Van Rooyen, D. M., Cooper, M., Robertson, A., Masters, S., Teoh, N. and Farrell, G. (2014). What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH. Australian Gastroenterology Week, Broadbeach, QLD, Australia, 22-24 october 2014. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736 |
|
2014 Conference Publication Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid ArthritisMcGarry, Trudy, Connolly, Mary, Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., O'Neill, Luke A., Veale, Douglas J. and Fearon, Ursula (2014). Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis. 78th Annual Meeting of the American College of Rheumatology/49th Annual Meeting of the Association of Rheumatology Health Professionals, Boston, MA United States, 14-19 November 2014. Hoboken, NJ United States: John Wiley and Sons. |
|
2014 Conference Publication MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseasesColl, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Dungan, Lara S., Munoz-Planillo, Raul, Monks, Brian G., Croker, Daniel E., Sutton, Caroline E., Stutz, Andrea, Nunez, Gabriel, Latz, Eicke, Kastner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matt A. and O'Neill, Luke A. J. (2014). MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases. 2nd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Melbourne Australia, Oct 26-29, 2014. London United Kingdom: Academic Press. doi: 10.1016/j.cyto.2014.07.037 |
|
2014 Conference Publication Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic FibrosisForrest, O., Ingersoll, S., Robertson, A. A., Preininger, M., Laval, J., Brown, M., O'Neill, L., Cooper, M. A., Tangpricha, V and Tirouvanziam, R. (2014). Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic Fibrosis. The 28th Annual North American Cystic Fibrosis Conference, Atlanta, GA United States, 9-11 October 2014. Hoboken, NJ United States: John Wiley and Sons. doi: 10.1002/ppul.23108 |
|
2014 Conference Publication Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in gliaDempsey, Colin, Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke and Lynch, Marina (2014). Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia. 12th International Congress of Neuroimmunology (ISNI), Mainz Germany, 9-13 November 2014. AMSTERDAM: ELSEVIER SCIENCE BV. doi: 10.1016/j.jneuroim.2014.08.393 |
|
2013 Journal Article Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomesColl, R. C., Robertson, A. A.B., Butler, M., Cooper, M. and O'Neill, L. A.J. (2013). Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 8 (7) e29539. doi: 10.1371/annotation/78d328b9-2c8c-4978-84b1-7e6a0b12ada1 |
|
2013 Journal Article Efficient synthesis of anacardic acid analogues and their antibacterial activitiesMamidyala, Sreeman K., Ramu, Soumya, Huang, Johnny X., Robertson, Avril A. B. and Cooper, Matthew A. (2013). Efficient synthesis of anacardic acid analogues and their antibacterial activities. Bioorganic & Medicinal Chemistry Letters, 23 (6), 1667-1670. doi: 10.1016/j.bmcl.2013.01.074 |
|
2012 Journal Article Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cellsLin, Y., Richards, F. M., Krippendorff, B - F., Bramhall, J. L., Harrington, J. A., Bapiro, T. E., Robertson, A., Zheleva, D. and Jodrell, D. I. (2012). Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. BJC, 107 (10), 1692-1701. doi: 10.1038/bjc.2012.450 |
|
2011 Journal Article The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomesColl, Rebecca C., Robertson, Avril, Butler, Mark, Cooper, Matthew and O'Neill, Luke A. J. (2011). The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 6 (12) e29539, e29539. doi: 10.1371/journal.pone.0029539 |
